Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer ; volume:12 ; number:1 ; day:28 ; month:9 ; year:2022 ; pages:1-8 ; date:12.2022
Scientific reports ; 12, Heft 1 (28.9.2022), 1-8, 12.2022

Urheber
Hakozaki, Yuji
Yamada, Yuta
Kawai, Taketo
Nakamura, Masaki
Takeshima, Yuta
Iwaki, Takuya
Teshima, Taro
Kinoshita, Yoshitaka
Fujii, Yoichi
Akiyama, Yoshiyuki
Sato, Yusuke
Yamada, Daisuke
Suzuki, Motofumi
Kashiwagi-Hakozaki, Mayu
Ushiku, Tetsuo
Kume, Haruki
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41598-022-20319-z
URN
urn:nbn:de:101:1-2022121621100884454222
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:24 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Hakozaki, Yuji
  • Yamada, Yuta
  • Kawai, Taketo
  • Nakamura, Masaki
  • Takeshima, Yuta
  • Iwaki, Takuya
  • Teshima, Taro
  • Kinoshita, Yoshitaka
  • Fujii, Yoichi
  • Akiyama, Yoshiyuki
  • Sato, Yusuke
  • Yamada, Daisuke
  • Suzuki, Motofumi
  • Kashiwagi-Hakozaki, Mayu
  • Ushiku, Tetsuo
  • Kume, Haruki
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer

PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer

Verbundene Objekte